Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations

By sjmartinez • August 2, 2024

Lara MS, Riess JW, Goldman JW, Jiang F, Bivona TG, Blakely CM. Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations. Clin Lung Cancer. 2024 Jul 5:S1525-7304(24)00140-2. doi: 10.1016/j.cllc.2024.07.002. Epub ahead of print. PMID: 39089913.

Tags: Capmatinib, Hematology/Oncology, MAPK signaling, MET exon skipping mutation, Non-small cell lung cancer, Publications, Trametinib

Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care Coordination in Safety-Net Systems

Tupper HI, Doo FX, Lin Y, Flores EJ, Salinas DA, Cummings AL, Ryan GW, Revels SL. Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care[...]

Epigenetic age acceleration measures and chemotoxicity in older adults with early breast cancer

Ji J, Sun CL, Dale W, Kim H, Katheria V, Lee C, Smith C, Sun N, Ding YC, Neuhausen SL, Cohen HJ, Binder A, Sedrak[...]

Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial

Hanna GJ, Zandberg DP, Wong DJ, Sherman E, Sacco AG, Yilmaz E, Hernando-Calvo A, Reiners RD, Bohr D, Salazar RL, O'Connell BC, Raben D, Schulten[...]